TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28027682

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum ointment
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Achillea millefolium ointment
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (placebo ointment)
Number of subjects: 140
Study: 26581685

Group type: EXPERIMENTAL
Intervention: Milk-based protein matrix (0.165 g/kg body mass)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoenergetic, nonnitrogenous maltodextrin control
Number of subjects: 60
Study: 25549639

Group type: EXPERIMENTAL
Intervention: Four-channel FES
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dual-channel FES
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comfort stimulation
Number of subjects: 48
Study: 22348270

Group type: EXPERIMENTAL
Intervention: Anti-static chamber (AeroChamber Plus Z-Stat)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Static chamber (AeroChamber Plus)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 7
Study: 20230404

Group type: EXPERIMENTAL
Intervention: Reduced cumulative anthracycline dose (350 mg/m2) combined with all-trans-retinoid acid (ATRA)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Salvage treatment with arsenic trioxide and stem cell transplantation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Anthracycline-cytarabine regimen
Number of subjects: 81
Study: 18713156

Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Propranolol 80 mg/day
Number of subjects: 62
Study: 15925739

Group type: EXPERIMENTAL
Intervention: Drospirenone/17-beta estradiol (DRSP/E2)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 12655535

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin after a single dose of intravenous ceftriaxone and amikacin (Group A)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (Group B)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (Group A)
Number of subjects: 135
Study: 10827885

Group type: COMPARATOR
Intervention: Placebo substitution for paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo substitution for sertraline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interruption of fluoxetine
Number of subjects: 0
Study: 8648360

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 500 mg twice daily
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 1498502

Group type: EXPERIMENTAL
Intervention: Bovine surfactant preparation (SF‐RI 1) administered endotracheally (50‐200 mg/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bovine surfactant preparation (SF‐RI 1)
Number of subjects: 34
Study: 6405437

Group type: COMPARATOR
Intervention: Intravenous alcohol infusion
Number of subjects: 10
Study: 31735560

Group type: EXPERIMENTAL
Intervention: Isatuximab 10 mg/kg plus pomalidomide 4 mg plus dexamethasone 40 mg (20 mg for patients aged ≥75 years)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Pomalidomide 4 mg plus dexamethasone 40 mg
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Isatuximab-pomalidomide-dexamethasone
Number of subjects: 307

Group type: COMPARATOR
Intervention: Pomalidomide-dexamethasone
Number of subjects: 307
Study: 30399455

Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (PDT) mediated by methylene blue
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ultrasonic scaler (US)
Number of subjects: 20
Study: 27829428

Group type: EXPERIMENTAL
Intervention: Aromatherapy QueaseEase™ (blend of ginger, lavender, mint and spearmint)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Aromatherapy QueaseEase™
Number of subjects: 39
Study: 25095886

Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 158

Group type: COMPARATOR
Intervention: Noninvasive treatment
Number of subjects: 158
Study: 22617578

Group type: EXPERIMENTAL
Intervention: Continuous oral contraceptive pills (gestodene 0.075 mg and ethinyl estradiol 20 microgram) for 6 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cyclic oral contraceptive pills (gestodene 0.075 mg and ethinyl estradiol 20 microgram) for 6 months
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Continuous oral contraceptive pills
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cyclic oral contraceptive pills
Number of subjects: 38
Study: 20223838

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (120 mg intramuscular injection)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Polyarthritis
Number of subjects: 383
Study: 18702687

Group type: EXPERIMENTAL
Intervention: Intermediate length adult colonoscope (CF‐240I)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Long pediatric colonoscope (PCF‐240L)
Number of subjects: 918
Study: 15640982

Group type: EXPERIMENTAL
Intervention: Short-segment, onset latency-based transcarpal mixed NCV
Number of subjects: 180

Group type: COMPARATOR
Intervention: Long-segment studies: antidromic wrist-to-digit sensory NCV without subtraction
Number of subjects: 180

Group type: COMPARATOR
Intervention: Short-segment studies: transcarpal palm-to-wrist mixed NCV without subtraction
Number of subjects: 180

Group type: COMPARATOR
Intervention: 2 segment studies: antidromic transcarpal sensory NCV with subtraction
Number of subjects: 180
Study: 12354441

Group type: EXPERIMENTAL
Intervention: Dual-site right atrial pacing
Number of subjects: 118
Study: 11144061

Group type: EXPERIMENTAL
Intervention: Treatment (specific treatment details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study: 8809925

Group type: EXPERIMENTAL
Intervention: Intensive dynamic exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dosage or short-time exercise programs
Number of subjects: 0
Study: 1667693

Group type: EXPERIMENTAL
Intervention: PGE1 infusion
Number of subjects: 48
Study: 6332953

Group type: EXPERIMENTAL
Intervention: Propranolol 0.05 mg/kg administered 4 to 5 minutes before aortic cross‐clamping
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combined propranolol group
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 98
Study: 31473932

Group type: EXPERIMENTAL
Intervention: GTO (Getting To Outcomes) implementation support intervention
Number of subjects: 29

Group type: COMPARATOR
Intervention: CHOICE (control group)
Number of subjects: 29
Study: 29725956

Group type: EXPERIMENTAL
Intervention: Sacchaflor (S. boulardii 5 × 10^9, Pharmaforce ApS) twice daily
Number of subjects: 1389

Group type: COMPARATOR
Intervention: Control hospitals (not specified)
Number of subjects: 1389
Study: 26956679

Group type: EXPERIMENTAL
Intervention: Culturally informed intervention including regular postcards, problem solving therapy, patient support, risk management, improved access to primary care, and cultural assessment in addition to usual care.
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Culturally informed intervention
Number of subjects: 167

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 167
Study: 24910105

Group type: EXPERIMENTAL
Intervention: Serum bilirubin concentrations
Number of subjects: 588
Study: 22499404

Group type: EXPERIMENTAL
Intervention: new Chest Physical therapy (nCPT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: conventional Chest Physical therapy (cCPT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: aspiration of the upper airways (Control)
Number of subjects: 30
Study: 20042424

Group type: EXPERIMENTAL
Intervention: Intracoronary transfer of autologous BM cells (4 + or - 1 days after PCI)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Optimized treatment only (Control group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intracoronary transfer of autologous BM cells
Number of subjects: 38
Study: 18620023

Group type: EXPERIMENTAL
Intervention: Topiramate 100mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 15693921

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 530
Study: 11804986

Group type: EXPERIMENTAL
Intervention: Lamifiban
Number of subjects: 5225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5225

Group type: EXPERIMENTAL
Intervention: Lamifiban (subgroup with plasma concentrations measured)
Number of subjects: 5225
Study: 11715499

Group type: EXPERIMENTAL
Intervention: Screening group (n=9,373) tested with serum AFP and real time ultrasound every 6 months
Number of subjects: 18816

Group type: COMPARATOR
Intervention: Control group (n=9,443) received no screening
Number of subjects: 18816
Study: 7790671

Group type: EXPERIMENTAL
Intervention: 35% CO2‐65% O2 gas mixture
Number of subjects: 59

Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 59
Study: 2218653

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 40
Study: 310269

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (HLI)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Human fibroblast interferon (HFI)
Number of subjects: 38
Study: 31279090

Group type: EXPERIMENTAL
Intervention: Multimedia Self-Management (MSM) intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 320
Study: 28590370

Group type: EXPERIMENTAL
Intervention: Early improvement at week 2 (defined as a reduction in the YMRS score of at least 20% or 25%)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Early improvement at week 2
Number of subjects: 350
Study: 25599220

Group type: EXPERIMENTAL
Intervention: MoviPrep + neostigmine methylsulfate and glycopyrrolate (MoviPrep+NG)
Number of subjects: 27

Group type: COMPARATOR
Intervention: MoviPrep alone
Number of subjects: 27

Group type: COMPARATOR
Intervention: MoviPrep alone (able-bodied group)
Number of subjects: 27
Study: 23551402

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg/kg) for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 100
Study: 20890683

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 72

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 72
Study: 18284510

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) pre-PVAI and 3 months post-PVAI
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE) pre-PVAI
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Comparison of EF between patients with and without LAA thrombus
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Comparison of LA size between patients with and without LAA thrombus
Number of subjects: 1221
Study: 16123763

Group type: EXPERIMENTAL
Intervention: Cocaine-related cues exposure during fMRI
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nonrelapsers (TES above mean and completed treatment)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Relapsers
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Physiological activation during fMRI
Number of subjects: 17
Study: 12739123

Group type: EXPERIMENTAL
Intervention: Laparoscopy followed by open appendicectomy if necessary
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open appendicectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal-looking appendix left at laparoscopy
Number of subjects: 0
Study: 10969348

Group type: EXPERIMENTAL
Intervention: Methadone therapy
Number of subjects: 27
Study: 10436992

Group type: EXPERIMENTAL
Intervention: Corticosteroid application in group A
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Corticosteroid application in group B
Number of subjects: 600
Study: 8790522

Group type: EXPERIMENTAL
Intervention: Vaginal ultrasonography
Number of subjects: 950

Group type: COMPARATOR
Intervention: No examination (Control)
Number of subjects: 950
Study: 2662234

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 76
Study: 813951

Group type: COMPARATOR
Intervention: Ibuprofen 300 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ibuprofen 600 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ibuprofen total daily dose 1,200 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ibuprofen total daily dose 2,400 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Warfarin 7.5 mg
Number of subjects: 36
Study: 31218718

Group type: EXPERIMENTAL
Intervention: Emotional letter
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Educational letter
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Phone reminder
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Incentives
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Motivational meeting
Number of subjects: 1356

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 1356
Study: 27932607

Group type: EXPERIMENTAL
Intervention: EG-1962 (800 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: EG-1962
Number of subjects: 72

Group type: COMPARATOR
Intervention: enteral nimodipine
Number of subjects: 72
Study: 25768241

Group type: EXPERIMENTAL
Intervention: QAC surfactant plus daily hypochlorite cleaning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypochlorite cleaning alone
Number of subjects: 0
Study: 23660437

Group type: EXPERIMENTAL
Intervention: Low dose of the DRD2 agonist bromocriptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21221531

Group type: EXPERIMENTAL
Intervention: Varenicline 2 mg daily (extended 4-week pretreatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual 1-week pretreatment (placebo lead in followed by active medication)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Varenicline (extended pretreatment)
Number of subjects: 30
Study: 19604499

Group type: EXPERIMENTAL
Intervention: Predictable shocks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unpredictable shocks
Number of subjects: 0
Study: 16978648

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15149423

Group type: EXPERIMENTAL
Intervention: Narrow QRS complex (QRS <120 ms)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intermediate QRS duration (QRS 120-150 ms)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Wide QRS complex (QRS >150 ms)
Number of subjects: 90

Group type: COMPARATOR
Intervention: QRS duration >120 ms
Number of subjects: 90
Study: 11157015

Group type: EXPERIMENTAL
Intervention: Self-directed exercise
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 123

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 123
Study: 8757207

Group type: EXPERIMENTAL
Intervention: Double-strength beclomethasone dipropionate (BDP-ds) aqueous nasal spray (84 micrograms/spray), once daily
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Regular-strength beclomethasone dipropionate (BDP-rs) aqueous nasal spray (42 micrograms/spray), twice daily
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: High-strength beclomethasone dipropionate (BDP-hs) aqueous nasal spray (336 micrograms/spray), once daily
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study: 1590575

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Midazolam/alfentanil
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 45

Group type: COMPARATOR
Intervention: Midazolam/alfentanil and Isoflurane
Number of subjects: 45
Study: 2997101

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir 250 mg/m2 once daily for four weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir 250 mg/m2 once daily
Number of subjects: 27
Study: 31420703

Group type: EXPERIMENTAL
Intervention: Cinnarizine (25 mg) plus Betahistine (8 mg) combination, administered three times a day for 1 week
Number of subjects: 162

Group type: COMPARATOR
Intervention: Betahistine (8 mg) plus placebo, administered three times a day for 1 week
Number of subjects: 162

Group type: COMPARATOR
Intervention: Cinnarizine (25 mg) plus placebo, administered three times a day for 1 week
Number of subjects: 162
Study: 28134006

Group type: EXPERIMENTAL
Intervention: Obesogenic environment
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Social support for health behaviours from mothers, fathers, teachers, classmates, and close friends
Number of subjects: 270
Study: 27291994

Group type: EXPERIMENTAL
Intervention: Immunoablation followed by autologous haemopoietic stem-cell transplantation (aHSCT)
Number of subjects: 24
Study: 23617556

Group type: EXPERIMENTAL
Intervention: Ambulatory physiotherapy (AP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No physiotherapy
Number of subjects: 70
Study: 22287743

Group type: EXPERIMENTAL
Intervention: E‐cadherin(+) patients treated with erlotinib
Number of subjects: 95

Group type: COMPARATOR
Intervention: E‐cadherin(‐) patients treated with placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: E‐cadherin(‐) patients treated with erlotinib
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Vimentin(+) patients treated with erlotinib
Number of subjects: 95

Group type: COMPARATOR
Intervention: Vimentin(+) patients treated with placebo
Number of subjects: 95

Group type: COMPARATOR
Intervention: Vimentin(‐) patients treated with placebo
Number of subjects: 95
Study: 19466744

Group type: EXPERIMENTAL
Intervention: Psychoeducational class intervention
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Small group counseling intervention
Number of subjects: 904

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 904
Study: 17459447

Group type: EXPERIMENTAL
Intervention: Attentional-set to ignore old, irrelevant distractors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attentional-set to prioritize old items
Number of subjects: 0
Study: 15237711

Group type: EXPERIMENTAL
Intervention: GnRH analog treatment (triptorelin or leuprolide acetate)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No treatment (control group B)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Triptorelin
Number of subjects: 37
Study: 12055702

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Simvastatin and atorvastatin
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cerivastatin
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 144
Study: 9829494

Group type: EXPERIMENTAL
Intervention: Intravenous rHuEpo (100 U/kg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Subcutaneous rHuEpo (100 U/kg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 39
Study: 7917157

Group type: EXPERIMENTAL
Intervention: Cortisol, 50 mg orally four times daily for 5 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Octreotide, 0.05 mg subcutaneously before and on the fifth day of cortisol administration
Number of subjects: 6
Study: 2194953

Group type: EXPERIMENTAL
Intervention: Nonsurgical therapeutic techniques (endoscopic sphincterotomy and biliary endoprostheses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 0
Study: 92159

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (Dermovat) 25 g and 15 g ointment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Betamethasone-17,21-dipropionate (Diproderm) 25 g ointment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Betamethasone-17,21-dipropionate (Diproderm) 10 g ointment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Post-treatment observation
Number of subjects: 32
Study: 31725676

Group type: EXPERIMENTAL
Intervention: Neuromuscular stretching group (NSG) - combining transcutaneous electrical nerve stimulation with static stretching of the plantar fascia
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study: 28012176

Group type: EXPERIMENTAL
Intervention: UE2343 (10 mg and above)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UE2343 (multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UE2343
Number of subjects: 0
Study: 25889354

Group type: EXPERIMENTAL
Intervention: 30 g protein meal
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 39 g protein meal
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low-protein pancake breakfast (3 g protein)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No breakfast (water)
Number of subjects: 35
Study: 23413849

Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ropivacaine
Number of subjects: 100
Study: 21104822

Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy plus PAND
Number of subjects: 690

Group type: COMPARATOR
Intervention: D2 lymphadenectomy alone
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: TH approach
Number of subjects: 690

Group type: COMPARATOR
Intervention: LTA approach
Number of subjects: 690
Study: 19962605

Group type: EXPERIMENTAL
Intervention: Xbow appliance
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 69
Study: 16464325

Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (five sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual management alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy
Number of subjects: 0
Study: 14679367

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100